福安藥業(300194.SZ)：2019年度業績扭虧為盈至2.93億元 擬10派0.5元
格隆匯3月27日丨福安藥業(300194.SZ)披露2019年年度報告，實現營業收入27.81億元，同比增長4.18%；歸屬於上市公司股東的淨利潤2.93億元，上年同期虧損3.6億元；歸屬於上市公司股東的扣除非經常性損益的淨利潤2.59億元，上年同期虧損3.83億元；基本每股收益0.25元；擬向全體股東每10股派發現金紅利0.50元(含税)。
2019年，公司依然面臨行業政策的變革與日趨激烈的外部市場競爭環境，藥品帶量集中採購、新醫保目錄談判准入、重點監控藥品目錄以及新藥品管理法的出台等一系列行業政策給市場參與主體帶來發展機遇的同時，也相應帶來壓力和挑戰。宏觀層面看，醫藥衞生體制改革的深入推進將對行業企業產生持續影響。
報告期，圍繞公司發展戰略和生產經營目標，經營團隊團結帶領全體員工落實董事會決策部署，抓好生產經營各環節工作，實現了公司業績扭虧為盈、穩步增長的良好局面。同時，公司也圍繞主業積極通過併購、參股、合作設立基金等多種形式，開展、推動在新領域的投資併購，以期抓住新興市場和潛力產品的發展機遇，進一步優化公司的產品結構和產業佈局，為未來發展和業績提升打下基礎。
報告期，公司銷售收入穩步增長，同比增長 4.18%。在藥品銷售“兩票制”在全國的持續推廣、帶量集中採購等政策的試點實施的大背景下，公司銷售工作面臨着挑戰和壓力，公司結合自身銷售網絡覆蓋情況，加強銷售隊伍管理、提高銷售人員業務素質，針對不同藥品、不同地域，結合政策情況採取差異化的銷售策略，加強與客户溝通合作，努力維護和開拓國內市場。同時，公司也繼續積極開拓海外市場，醫藥相關產品銷售區域逐步擴大至亞洲、歐洲、美洲等多個國家和地區。
報告期，公司繼續把藥品研發能力作為核心競爭力來抓，結合行業政策和市場變化情況，適度調整研發策略，採取多種合作方式開展研發，推動在研項目進展，積極啟動藥品一致性評價工作，持續加大研發投入以保證公司研發工作的連續性和前瞻性，服務於公司戰略發展。報告期，公司研發投入13,820.02萬元，同比增長29.29%。
報告期，公司獲得鹽酸氨溴索注射液、鹽酸託烷司瓊注射液藥品註冊批件。注射用氨曲南、枸櫞酸託瑞米芬片、注射用頭孢他啶、注射用克林黴素磷酸酯、注射用替加環素、多索茶鹼注射液、注射用艾司奧美拉唑鈉、注射用頭孢米諾鈉、門冬氨酸鳥氨酸注射液等藥品的一致性評價獲得受理。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
